Spyre Therapeutics, INC 8-K filings

Spyre Therapeutics announced positive Q2 2026 financial results, highlighting strong clinical trial data for SPY001 and SPY002, completion of enrollment in the SKYWAY trial, and a substantial cash reserve.

Spyre Therapeutics reported positive 12-week induction data from its Phase 2 SKYLINE trial for SPY002 in ulcerative colitis, meeting primary and secondary endpoints with a favorable safety profile.

Spyr Therapeutics amended its license agreement with Paragon Therapeutics to broaden the therapeutic applications for its SPY003 drug beyond inflammatory bowel disease.

Spyre Therapeutics stockholders approved an amended employee stock purchase plan and elected three directors at the 2026 Annual Meeting.

Spyre Therapeutics announced positive Phase 2 data for SPY001 in IBD and provided updates on its rheumatic disease trials, alongside a strengthened balance sheet.

Spyre Therapeutics has successfully closed a public offering of 7,475,000 shares of common stock, generating approximately $463.5 million in gross proceeds.

Spyre Therapeutics announced preliminary cash reserves of approximately $741 million as of March 31, 2026, and terminated its at-the-market prospectus.

Spyre Therapeutics reports positive 12-week induction topline data from its Phase 2 SKYLINE trial for SPY001 in ulcerative colitis, meeting primary and secondary endpoints.

Spyre Therapeutics announced its fourth quarter and full year 2025 financial results, highlighting significant progress in its Phase 2 clinical trials and a strong cash position.

Spyre Therapeutics announced accelerated clinical trial readouts for its IBD program, key appointments, and a strong financial position extending its cash runway into late 2028.

Spyre Therapeutics announced positive interim Phase 1 results for its SPY003 antibody and reported its third-quarter 2025 financial results, including a strengthened cash position.

Spyre Therapeutics, Inc. successfully closed a public offering of 17,094,594 shares of common stock at $18.50 per share, generating approximately $316.2 million in gross proceeds.

Spyre Therapeutics announced preliminary cash, cash equivalents, and marketable securities of approximately $486.2 million as of September 30, 2025.

Spyre Therapeutics announced its second quarter 2025 financial results and provided positive updates on its clinical pipeline, including interim Phase 1 data and initiation of Phase 2 trials for its inflammatory bowel disease and rheumatic disease programs.

Spyre Therapeutics announced positive interim Phase 1 results for its investigational anti-TL1A antibodies, SPY002 and SPY072, demonstrating favorable safety and prolonged half-life, and unveiled plans for extensive Phase 2 trials in inflammatory bowel disease and rheumatologic conditions.

Spyre Therapeutics, Inc. announced the results of its Annual Meeting of Stockholders held on May 29, 2025, where key proposals including director elections, executive compensation approval, and auditor ratification were passed.

Spyre Therapeutics announces its Q1 2025 financial results, highlighting progress in clinical trials and a strong cash position.

Spyre Therapeutics dismisses PricewaterhouseCoopers LLP and appoints KPMG LLP as its new independent registered public accounting firm, effective immediately on February 28, 2025.

Spyre Therapeutics announced positive interim Phase 1 data for SPY001, a strong cash position of $603 million, and progress across its portfolio in its fourth quarter and full year 2024 financial results.

Spyre Therapeutics is advancing its pipeline with upcoming clinical readouts, an expansion into rheumatoid arthritis, and a strong cash position.

Spyre Therapeutics has entered into an underwriting agreement to sell 7,275,000 shares of common stock at $27.50 per share, expecting to raise approximately $200 million to fund operations into the second half of 2028.

Spyre Therapeutics has announced a restatement of its previously issued financial statements due to an error in the calculation of net loss per share, specifically related to the treatment of preferred stock.

Spyre Therapeutics reports positive interim Phase 1 results for SPY001, showing a significantly extended half-life and complete target engagement, supporting potential for quarterly or bi-annual maintenance dosing in inflammatory bowel disease.

Spyre Therapeutics announced its third quarter 2024 financial results, highlighting advancements in its IBD pipeline and a strong cash position.

Spyre Therapeutics announces the expected acceleration of its SPY003 clinical timelines and presents new preclinical data supporting its portfolio of antibody and combination therapies for inflammatory bowel disease.

Spyre Therapeutics has filed an amended 8-K report to correct a clerical error regarding the date of the original filing, which was August 7, 2024.

Spyre Therapeutics reports progress in its IBD pipeline, including the initiation of a Phase 1 trial for SPY001 and advancement of SPY002 and SPY003, alongside a solid cash position of $426 million.

Spyre Therapeutics reports an increase in outstanding common stock shares following the conversion of Series A and B preferred stock.

Spyre Therapeutics has entered into exclusive licensing agreements for two antibody programs, amended an existing agreement, appointed a new director, and updated its corporate structure.

Spyre Therapeutics announced its first quarter 2024 financial results, highlighted by a successful $180 million private placement and progress in its IBD pipeline.